News & Updates
Showing Dermatology articles
Showing

New oral tyrosine kinase 2 inhibitor shows promise against moderate-to-severe plaque psoriasis
PF-06826647, a novel tyrosine kinase 2 inhibitor in development, outperforms placebo at reducing disease severity in patient with moderate-to-severe plaque psoriasis, reveals a new trial.

Abrocitinib effectively manages AD flares
Rescue therapy using the Janus kinase 1 inhibitor abrocitinib combined with topical medicated therapy recaptured efficacy responses and had a favourable safety profile in individuals with moderate-to-severe atopic dermatitis (AD) who experienced flare during the maintenance period of the phase III randomized-withdrawal JADE REGIMEN trial.

Antihypertensive drugs up risk of psoriasis
Use of antihypertensive medications is associated with the incidence of psoriasis, reports a study. Beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), and thiazide diuretics result in an increased risk of psoriasis.





